Use of Response Surface Methodology in the Formulation and Optimization of Bisoprolol Fumarate Matrix Tablets for Sustained Drug Release

Table 1

The formulation chart for all proposed trial formulations of bisoprolol fumarate matrix tablets.

Formulation codes	Drug; (mg)	Calcium alginate (mg); (𝐴)	HPMC K4M (mg); (𝐵)	Carbopol 943 (mg); (𝐶)	Lactose; (mg)	MCC; (mg)^a	Mg-stearate; (mg)
F-1	20	15 (−1)	0 (−1)	0 (−1)	70	20	10
F-2	20	30 (+1)	20 (+1)	20 (+1)	70	20	10
F-3	20	30 (+1)	0 (−1)	0 (−1)	70	20	10
F-4	20	30 (+1)	20 (+1)	0 (−1)	70	20	10
F-5	20	15 (−1)	20 (+1)	20 (+1)	70	20	10
F-6	20	15 (−1)	0 (−1)	20 (+1)	70	20	10
F-7	20	30 (+1)	0 (−1)	20 (+1)	70	20	10
F-8	20	15 (−1)	20 (+1)	0 (−1)	70	20	10

^aMCC: Microcrystalline cellulose; 𝑋₁, 𝑋₂, and 𝑋₃ represent the main effects (factors); (+1): higher value and (−1): lower value.